SPY314.38-1.80 -0.57%
DIA257.24-3.48 -1.33%
IXIC10,547.75+55.25 0.53%

Aileron Therapeutics Initiates Enrollment In Schedule Optimization Part Of Phase 1b/2 Study Of ALRN-6924 As A Chemoprotection Agent In Small Cell Lung Cancer (SCLC) Patients Being Treated With Topotecan

Benzinga · -